Search Results - "HUININK, WIM W.TEN BOKKEL"

Clinical pharmacology of anticancer agents in relation to formulations and administration routes by Terwogt, Jetske M.Meerum, Schellens, Jan H.M., Huinink, Wim W.ten Bokkel, Beijnen, Jos H.

“…In the past years, alternative administration routes and pharmaceutical formulations of anticancer agents have been investigated in order to improve…”
Get full text

Surveillance can be the standard of care for stage I nonseminomatous testicular tumors and even high risk patients by Roeleveld, T A, Horenblas, S, Meinhardt, W, van de Vijver, M, Kooi, M, ten Bokkel Huinink, W W

“…We investigate the results of a surveillance program for stage I nonseminomatous germ cell tumors to validate a surveillance policy, and furthermore improve it…”
Get more information

Phase I Pharmacokinetic and Pharmacodynamic Study of Carboplatin and Topotecan Administered Intravenously Every 28 Days to Patients with Malignant Solid Tumors by BOSS, David S, SIEGEL- LAKHAI, Wandena S, VAN EGMOND-SCHOEMAKER, Nadja E, PLUIM, Dick, ROSING, Hilde, TEN BOKKEL HUININK, Wim W, BEIJNEN, Jos H, SCHELLENS, Jan H. M

“…Purpose: Preclinical studies have shown that the combination of topotecan and carboplatin is synergistic. To evaluate the schedule dependency of this…”
Get full text

PHARMACOKINETICS OF PACLITAXEL ADMINISTERED AS A 3-HOUR OR 96-HOUR INFUSION by PANDAY, VINODH R.NANNAN, HUININK, WIM W.TEN BOKKEL, VERMORKEN, JAN B., ROSING, HILDE, KOOPMAN, FRANCISCA J., SWART, MARTHA, SCHELLENS, JAN H.M., BEIJNEN, JOS H.

“…Aim: To investigate the pharmacokinetics of paclitaxel (PaxeneTM) administered to patients with advanced breast or ovarian cancer and to document safety and…”
Get full text

PHARMACOLOGIC STUDY OF 3-HOUR 135 mg m−2PACLITAXEL IN PLATINUM PRETREATED PATIENTS WITH ADVANCED OVARIAN CANCER by PANDAY, VINODH R.NANNAN, HUIZING, MANON T., van WARMERDAM, LAURENCE J.C., DUBBELMAN, RIA C., MANDJES, INGRID, SCHELLENS, JAN H.M., HUININK, WIM W.TEN BOKKEL, BEIJNEN, JOS H.

“…Paclitaxel (Taxol®) is an active agent in platinum–refractory ovarian cancer. Since the available pharmacokinetic data of 135 mg m−2paclitaxel administered by…”
Get full text

Multicenter phase II study of spiroplatin by Tanis, B C, Vermorken, J B, ten Bokkel Huinink, W W, van Oosterom, A T, Splinter, T A, Vendrik, K J, Sleijfer, D T, van der Burg, M E, van der Putten, E, Pinedo, H M

“…Spiroplatin was investigated in a multicenter phase II study, during which the drug was given over 4 h. 64 Patients with nine different solid tumors received…”
Get more information